Breaking News

Catalent, J&J Enter Mfg. Pact for COVID-19 Vax Candidate

Includes joint investment and tech transfer to prepare for rapid scale-up and cGMP commercial manufacturing at Catalent's Bloomington facility.

By: Contract Pharma

Contract Pharma Staff

Catalent, Inc. has entered a collaboration with the Janssen Pharmaceutical Companies of Johnson & Johnson, under which Catalent’s Biologics business unit will accelerate availability of manufacturing capacity and prepare for large-scale commercial manufacturing of J&J’s lead vaccine candidate for COVID-19 at its facility in Bloomington, IN.   The joint investment will accelerate rapid scale-up of segregated manufacturing capacity in the coming months to support dedicated production of ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters